Zanolimumab
- Generic Name
- Zanolimumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 652153-01-0
- Unique Ingredient Identifier
- HG3L8885M0
- Background
Zanolimumab is a fully human monoclonal antibody directed against CD4.
- Associated Conditions
- -
- Associated Therapies
- -
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-07-12
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 9
- Registration Number
- NCT01160445
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.
- First Posted Date
- 2003-10-15
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Genmab
- Target Recruit Count
- 25
- Registration Number
- NCT00071071
- Locations
- ๐บ๐ธ
Stanford University Med. Ctr., Dept. of Dermatology, Stanford, California, United States
๐บ๐ธUniversity of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States
Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.
- First Posted Date
- 2003-10-15
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Genmab
- Target Recruit Count
- 22
- Registration Number
- NCT00071084
- Locations
- ๐บ๐ธ
Stanford University Med Ctr., Dept of Dermatology, Stanford, California, United States
๐บ๐ธUniversity of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States
Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker
- First Posted Date
- 2002-08-01
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Genmab
- Target Recruit Count
- 83
- Registration Number
- NCT00042406
- Locations
- ๐บ๐ธ
Arthritis Center of Reno, Reno, Nevada, United States
๐บ๐ธRheumatology Associates, P.C., Chicago, Illinois, United States
๐บ๐ธAdvances in Medicine, Rancho Mirage, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.